Pro-tumorigenic Non-pump Function of Sodium Iodide Symporter: A Reimagined Trojan Horse?

Overview

Journal Oncotarget

Specialty Oncology

Date 2019 Feb 19

PMID 30774768

Citations 3

Authors

Fang Feng

Lamis Yehia

Charis Eng

Affiliations

Soon will be listed here.

Citing Articles

Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers.

Oh J, Rajendran R, Gangadaran P, Hong C, Jeong J, Lee J Cancers (Basel). 2022; 14(7).

PMID: 35406554 PMC: 8997411. DOI: 10.3390/cancers14071782.

Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.

Oh J, Ahn B Theranostics. 2021; 11(13):6251-6277.

PMID: 33995657 PMC: 8120202. DOI: 10.7150/thno.57689.

The Year in Basic Thyroidology.

Cheng S Thyroid. 2019; 30(1):8-12.

PMID: 31822204 PMC: 6983739. DOI: 10.1089/thy.2019.0768.

References

Tazebay U, Wapnir I, Levy O, Dohan O, Zuckier L, Zhao Q . The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000; 6(8):871-8. DOI: 10.1038/78630. View

Spitzweg C, OConnor M, Bergert E, Tindall D, Young C, Morris J . Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000; 60(22):6526-30. View

Dohan O, Baloch Z, Banrevi Z, LiVolsi V, Carrasco N . Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001; 86(6):2697-700. DOI: 10.1210/jcem.86.6.7746. View

Smith V, Read M, Turnell A, Watkins R, Watkinson J, Lewy G . A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci. 2009; 122(Pt 18):3393-402. PMC: 2736868. DOI: 10.1242/jcs.045427. View

Navarra M, Micali S, Lepore S, Cesinaro A, Celano M, Sighinolfi M . Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology. 2009; 75(4):773-8. DOI: 10.1016/j.urology.2009.10.011. View

Kogai T, Brent G . The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135(3):355-70. PMC: 3408573. DOI: 10.1016/j.pharmthera.2012.06.007. View

Lacoste C, Herve J, Bou Nader M, Dos Santos A, Moniaux N, Valogne Y . Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 2012; 72(21):5505-15. DOI: 10.1158/0008-5472.CAN-12-0516. View

Chekhun V, Andriiv A, Lukianova N . Significance of iodine symporter for prognosis of the disease course and efficacy of neoadjuvant chemotherapy in patients with breast cancer of luminal and basal subtypes. Exp Oncol. 2017; 39(1):65-68. View

Feng F, Yehia L, Ni Y, Chang Y, Jhiang S, Eng C . A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling. Cancer Res. 2018; 78(21):6121-6133. PMC: 6214770. DOI: 10.1158/0008-5472.CAN-18-1954. View

10.

Levy O, de la Vieja A, Ginter C, Riedel C, Dai G, Carrasco N . N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J Biol Chem. 1998; 273(35):22657-63. DOI: 10.1074/jbc.273.35.22657. View